QTTB
Q32 Bio Inc.
Next earnings Aug 4, 2026 · consensus $-0.57 EPS
Last earnings +2.0% on 2026-05-05
$13.17
▲ +10.21%$13.17▲ +749.68%
over 1Y
L $1.36EODHDH $14.00
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+10.2%
1W+4.1%
1M+2.5%
3M+81.7%
YTD+282.8%
1Y+749.7%
Buy
Conviction
Horizon
Medium (3–12mo)
Street · 11 analysts
Buy
Strong net margin (55.5%).
The read
Quality fundamentals and an attractive price line up (~598% below fair value) — the rarer case where both the business and the entry look good.
Q32 Bio Inc. shows $53.7M in FY2025 revenue, a 55.5% net margin, and 71.0% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | -$6.65M | $0.00 | $53.7M |
| Gross profit | — | — | — | — | — |
| Operating income | -$95.9M | -$133M | -$48.3M | -$66.1M | $16.9M |
| Net income | -$95.8M | -$5.00M | -$53.7M | -$47.7M | $29.8M |
| Diluted EPS | -$1.73 | -$0.09 | -$153.96 | -$6.58 | $2.42 |
| Net margin | — | — | 808.0% | — | 55.5% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$144M
EV / EBITDA—
EV / Sales2.7
EV / FCF—
P / FCF—
PEG (trailing)0.03
Earnings yield15.5%
FCF yield-17.4%
Quality & risk
ROIC (est.)31.8%
Free cash flow-$33.5M
Total debt—
Net cash$48.3M
Altman Z-Score3.83 safe
Piotroski F-Score3/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+19.9%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗S-3Filing2026-06-25open ↗4Period ending 2026-06-122026-06-16open ↗4Period ending 2026-06-122026-06-16open ↗4Period ending 2026-06-122026-06-16open ↗4Period ending 2026-06-122026-06-16open ↗4Period ending 2026-06-122026-06-16open ↗4Period ending 2026-06-122026-06-16open ↗4Period ending 2026-06-122026-06-16open ↗4Period ending 2026-06-122026-06-16open ↗8-KPeriod ending 2026-06-122026-06-16open ↗3Period ending 2026-05-262026-06-08open ↗SCHEDULE 13GFiling2026-06-04open ↗
Frequently asked
- Is Q32 Bio Inc. (QTTB) a buy?
- QTTB currently carries a Buy rating with 4/5 conviction, derived from its latest SEC filings. Strong net margin (55.5%).
- What is QTTB's fair value?
- A Modified-Graham model based on QTTB's SEC fundamentals estimates a fair value of about $91.96. It is an estimate from reported earnings, not a price target.
- Is QTTB overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, QTTB currently appears undervalued relative to its SEC-grounded earnings power.
- What is Q32 Bio Inc.'s quality score?
- QTTB scores 89.15686274509802/100 (grade A) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001661998, latest 10-Q filed 2026-05-05) · EODHD · as of 6/26/2026, 7:08:07 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.